This company listing is no longer active
SciClone Pharmaceuticals (Holdings) Management
Management criteria checks 2/4
SciClone Pharmaceuticals (Holdings)'s CEO is Hong Zhao, appointed in Jun 2020, has a tenure of 4.08 years. total yearly compensation is CN¥25.33M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 0.18% of the company’s shares, worth HK$20.59M. The average tenure of the management team and the board of directors is 2.1 years and 3.4 years respectively.
Key information
Hong Zhao
Chief executive officer
CN¥25.3m
Total compensation
| CEO salary percentage | 32.6% |
| CEO tenure | 4.1yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.1yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings
Apr 02
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today
Dec 14Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Jun 19SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's
May 31Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Feb 17Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Dec 02We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings
Oct 04SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings
Jul 27An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued
Jun 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | CN¥25m | CN¥8m | CN¥1b |
| Sep 30 2023 | n/a | n/a | CN¥1b |
| Jun 30 2023 | n/a | n/a | CN¥953m |
| Mar 31 2023 | n/a | n/a | CN¥904m |
| Dec 31 2022 | CN¥17m | CN¥8m | CN¥855m |
| Sep 30 2022 | n/a | n/a | CN¥844m |
| Jun 30 2022 | n/a | n/a | CN¥833m |
| Mar 31 2022 | n/a | n/a | CN¥878m |
| Dec 31 2021 | CN¥26m | CN¥7m | CN¥923m |
| Sep 30 2021 | n/a | n/a | CN¥837m |
| Jun 30 2021 | n/a | n/a | CN¥779m |
| Mar 31 2021 | n/a | n/a | CN¥766m |
| Dec 31 2020 | CN¥29m | CN¥7m | CN¥754m |
| Sep 30 2020 | n/a | n/a | CN¥817m |
| Dec 31 2019 | CN¥15m | CN¥6m | CN¥615m |
Compensation vs Market: Hong's total compensation ($USD3.48M) is above average for companies of similar size in the Hong Kong market ($USD513.78K).
Compensation vs Earnings: Hong's compensation has increased by more than 20% in the past year.
CEO
Hong Zhao (61 yo)
4.1yrs
Tenure
CN¥25,334,000
Compensation
Mr. Hong Zhao has been President and Chief Executive Officer at SciClone Pharmaceuticals (Holdings) Limited since June 24, 2020 and also serves as its Executive Director since June 24, 2020. Mr. Zhao serve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 4.1yrs | CN¥25.33m | 0.18% HK$ 20.6m | |
| Company Secretary | less than a year | CN¥6.92m | 0.026% HK$ 3.0m | |
| VP & Head of Technical Operations and Pharmacovigilance | 2.5yrs | no data | no data | |
| VP & Head of Immunization Business Unit | no data | no data | no data | |
| VP and Head of Market Access & Commercial Operation (MACO) Department | no data | no data | no data | |
| VP and Head of Registration & Pharmaceutical Affairs Department | no data | no data | no data | |
| VP, GM of Research and Development & Chief Medical Officer | 2.1yrs | no data | no data | |
| VP & Chief Business Development Officer | less than a year | no data | no data |
2.1yrs
Average Tenure
55yo
Average Age
Experienced Management: 6600's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 4.1yrs | CN¥25.33m | 0.18% HK$ 20.6m | |
| Company Secretary | 1.2yrs | CN¥6.92m | 0.026% HK$ 3.0m | |
| Non-Executive Director | 3.9yrs | CN¥658.00k | no data | |
| Independent Non-Executive Director | 3.4yrs | CN¥658.00k | no data | |
| Non-Executive Chairman | 4.1yrs | no data | no data | |
| Independent Non-Executive Director | 3.4yrs | CN¥658.00k | no data | |
| Non-Executive Director | 3.4yrs | no data | no data | |
| Independent Non-Executive Director | 3.4yrs | CN¥658.00k | no data | |
| Independent Non-Executive Director | 3.4yrs | CN¥658.00k | no data |
3.4yrs
Average Tenure
61yo
Average Age
Experienced Board: 6600's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/09 05:56 |
| End of Day Share Price | 2024/07/03 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SciClone Pharmaceuticals (Holdings) Limited is covered by 10 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | B. Riley Wealth |
| Hamed Khorsand | BWS Financial Inc. |
| Hangci Zheng | China International Capital Corporation Limited |